Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 3 for:    CPI-1205

ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03525795
Recruitment Status : Active, not recruiting
First Posted : May 16, 2018
Last Update Posted : January 7, 2019
Sponsor:
Information provided by (Responsible Party):
Constellation Pharmaceuticals

Brief Summary:
This is a Phase 1/2, multi-center, open-label study of CPI-1205 + ipilimumab in patients with histologically or cytologically confirmed advanced solid tumors. This study is designed to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of CPI-1205 + ipilimumab in patients with advanced solid tumors. Patients in Phase 2 will be treated at the RP2D of CPI-1205 + ipilimumab.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumors Drug: CPI-1205 Drug: ipilimumab Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study of CPI-1205 With Ipilimumab in Patients With Advanced Solid Tumors Followed by a Phase 2 Basket Study of CPI-1205 With Ipilimumab in Selected Tumor Types Previously Treated With PD-1 or PD-L1 Inhibitors
Actual Study Start Date : December 14, 2017
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Ipilimumab

Arm Intervention/treatment
Experimental: CPI-1205 Combination with ipilimumab Drug: CPI-1205
Administered orally

Drug: ipilimumab
Administered intravenously




Primary Outcome Measures :
  1. Phase 1: Frequency of Dose-limiting toxicities (DLTs) [ Time Frame: 1 year ]
    The RP2D will be selected based on the PK, pharmacodynamics and overall tolerability of the regimen, but will not exceed the MTD.

  2. Phase 2: Objective response rate [ Time Frame: 1 year ]
    The rate of confirmed complete responses (CR) + partial responses (PR) as determined by RECIST 1.1 criteria


Secondary Outcome Measures :
  1. Objective response rate [ Time Frame: 1 year ]
    The rate of confirmed iCR + iPR

  2. Clinical Benefit Rate [ Time Frame: 3 months ]
    The rate of CR + PR + stable disease (SD) after 3 months of treatment as determined by RECIST 1.1 criteria and as the rate of iCR + iPR + iSD after 3 months of treatment by iRECIST criteria

  3. Time to response [ Time Frame: 1 year ]
    The time from day (D) 1 of treatment to the date of first response as determined by RECIST 1.1 and iRECIST criteria

  4. Duration of Response [ Time Frame: 1 year ]
    The time from measurement criteria are first met for CR/PR or iCR/iPR (whichever is first recorded) until the date of recurrence or progressive disease as determined by RECIST 1.1 and iRECIST criteria

  5. Duration of treatment [ Time Frame: 1 year ]
    The time from D1 of treatment until the date treatment is discontinued for any reason

  6. Progression free survival [ Time Frame: 6 months ]
    The time from D1 of treatment to the date of progression or death, whichever occurs first with progressive disease as determined by RECIST 1.1 and iRECIST criteria

  7. Adverse Events [ Time Frame: 1 year ]
    AEs will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 4.03 (CTCAE v4.03).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18 years
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Diagnosis and Prior Treatment:
  • Phase 1: Patients with histologically or cytologically confirmed locally advanced (unresectable) or metastatic solid tumors and with progressive disease during or after treatment with a PD-1 or PD-L1-inhibitor who meet one of the following criteria:

    1. Relapsed following or progressed through standard therapy
    2. Have a disease for which no standard effective therapy exists (i.e., a therapy that demonstrates a significant increase in survival)
    3. Not a candidate for standard effective therapy NOTE: In men with prostate cancer, baseline testosterone levels must also be ≤50ng/dL (≤ 2.0nM) and surgical or ongoing medical castration must be maintained throughout the duration of the study.
  • Phase 2: Patients with histologically or cytologically confirmed diagnosis of one of the following and with progressive disease during or after treatment with a PD-1 or PD-L1-inhibitor:

    1. Cohort A: unresectable or metastatic melanoma
    2. Cohort B: metastatic NSCLC
    3. Cohort C: advanced or metastatic (stage 4) RCC
    4. Cohort D: unresectable or metastatic urothelial carcinoma (urethra, bladder, ureters, or renal pelvis)
  • If patient has known brain metastases, must have stable neurologic status following local therapy for at least 4 weeks without the use of steroids or on stable or decreasing dose of ≤10 mg daily prednisone (or equivalent), and must be without neurologic dysfunction that would confound the evaluation of neurologic and other adverse events (AEs).
  • Phase 1: patients may have measurable or non-measurable disease; measurable disease via RECIST 1.1 is required for Phase 2 patients
  • Recovery from recent surgery, radiotherapy, chemotherapy or any other anti-cancer therapy to baseline or ≤ Grade 1 (other than alopecia); ≤ Grade 2 neuropathy allowed
  • Demonstrate adequate organ function
  • Ability to swallow and retain oral medications

Exclusion Criteria:

  • Carcinomatous meningitis
  • Prior treatment with CTLA-4 inhibitor
  • Phase 2 Cohort: ocular melanoma
  • Experienced an immune-related adverse event (irAE) that led to permanent discontinuation of prior immunotherapy
  • History of severe hypersensitivity reaction to treatment with another monoclonal antibody
  • History of interstitial lung disease, idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest computed tomography (CT) scan; NOTE: history of radiation pneumonitis in the radiation field (fibrosis) is permitted.
  • Active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
  • Known history of human immunodeficiency virus (HIV) (HIV1/2 antibodies)
  • Gastrointestinal (GI) disorder that negatively affects absorption

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03525795


Locations
Layout table for location information
United States, Michigan
START Midwest
Grand Rapids, Michigan, United States, 49546
United States, Texas
The University of Texas - MD Anderson Cancer Center
Houston, Texas, United States, 77030
South Texas Oncology & Hematology
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Constellation Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Debbie Johnson Constellation Pharmaceuticals

Layout table for additonal information
Responsible Party: Constellation Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03525795     History of Changes
Other Study ID Numbers: 1205-202
First Posted: May 16, 2018    Key Record Dates
Last Update Posted: January 7, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Constellation Pharmaceuticals:
Phase 1/2
Oncology
EZH2 Inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Ipilimumab
(R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
Antineoplastic Agents, Immunological
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action